WPIC, 1941 East Rd., Houston, TX 77054, USA.
Expert Opin Pharmacother. 2012 Oct;13(15):2207-13. doi: 10.1517/14656566.2012.721778. Epub 2012 Sep 7.
Guanfacine extended release (GXR) is an alpha 1A noradrenergic agonist that has been approved by the FDA for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) as a monotherapy, and as an adjunctive therapy to stimulants for the treatment of ADHD in children and adolescents age 6 - 17.
PubMed, the Ovid Medline database, and the PsycInfo database were searched using the term 'guanfacine'. Results were then limited to criteria such as English and human, from 1990 through December 2011. The resulting yield from the comprehensive literature search was 4391 articles. The titles and abstracts of all articles were reviewed. Studies were selected for full-text review based upon their place in the hierarchy of evidence (e.g., randomized controlled trials), relevance and quality of individual studies, and generalizability to clinical practice. The search was augmented by further search of article reference lists. A total of 15 articles were selected for full-text examination.
Due to the absence of positive evidence for the efficacy of GXR for monotherapy in adolescents, clinicians should be guarded in the use of GXR for monotherapy in adolescents with ADHD. The use of GXR has considerable promise as an adjunct to stimulants for other behavioral conditions associated with ADHD.
胍法辛缓释剂（GXR）是一种α1A 去甲肾上腺素能激动剂，已被 FDA 批准用于治疗注意缺陷多动障碍（ADHD），作为一种单一疗法，以及作为辅助治疗兴奋剂治疗 6-17 岁儿童和青少年的 ADHD。
使用术语“胍法辛”在 PubMed、Ovid Medline 数据库和 PsycInfo 数据库中进行了搜索。结果然后仅限于英语和人类的标准，时间范围从 1990 年到 2011 年 12 月。全面文献搜索的结果产生了 4391 篇文章。审查了所有文章的标题和摘要。根据证据等级（例如，随机对照试验）、个体研究的相关性和质量以及对临床实践的普遍性，选择研究进行全文审查。通过进一步搜索文章参考文献列表来扩充搜索。共有 15 篇文章被选为全文检查。
由于缺乏 GXR 作为单一疗法治疗青少年 ADHD 的疗效的阳性证据，临床医生应谨慎使用 GXR 作为青少年 ADHD 的单一疗法。GXR 作为兴奋剂治疗其他与 ADHD 相关的行为障碍的辅助药物具有很大的应用前景。
